Skip to main navigation

DEFLATEHAE.COM
Investors & News
Careers
Contact

Disease Focus
Community Commitment
Scientific Approach
- Our Science
- Pipeline
Scientific Publications
About Pharvaris

Disease Focus
Community Commitment
Scientific Approach
- Our Science
- Pipeline
Scientific Publications
About Pharvaris

DEFLATEHAE.COM
Investors & News
Careers
Contact

Events

Investor Menu

IR Nav

Overview
News & Events
News Releases Events Publications
Financials
SEC Filings Quarterly Results
Stock
Stock Performance Analyst Coverage
Corporate Governance
Governance Documents Leadership Board of Directors Committee Composition
Resources
Investor FAQs Contact Us Email Alerts

Past Events

Apr 4 - Apr 6, 2025

CIIC Spring 2025 Conference

Supporting Materials

Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Data Snapshot Results of the CHAPTER-1 Open-Label Extension Study 1 MB

Mar 30 - Apr 3, 2025

Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2025

Supporting Materials

Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study 393.8 KB

Long-Term Safety, Efficacy and Health-Related Quality of Life of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Results of the CHAPTER-1 Open-Label Extension Study 473.5 KB

Mar 27 - Mar 29, 2025

4th ITACA National Congress

Supporting Materials

Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Data Snapshot Results of the CHAPTER-1 Open-Label Extension Study 451.5 KB

Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study (Oral Presentation) 353.5 KB

Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study (Poster) 375.4 KB

Mar 7 - Mar 9, 2025

2025 HAE International (HAEi) Regional Conference APAC

Supporting Materials

Deucrictibant vs. Standard of Care in Hereditary Angioedema: A Propensity Score-Matched Analysis 274.4 KB

Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylactic and On-Demand Treatment of Hereditary Angioedema Attacks: Results of the ongoing CHAPTER-1 and RAPIDe-2 Extension Trials 719.1 KB

Feb 28 - Mar 3, 2025

2025 American Academy of Allergy, Asthma & Immunology (AAAAI) and World Allergy Organization (WAO) Joint Congress

Supporting Materials

Long-Term Prophylactic Treatment with Oral Deucrictibant Improves Health-Related Quality of Life of Patients With Hereditary Angioedema: CHAPTER-1 Open-Label Extension Study 229.4 KB

Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension 214.8 KB

Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Results of the CHAPTER-1 Open-Label Extension Study 430.7 KB

Feb 9 - Feb 13, 2025

Western Society of Allergy, Asthma & Immunology (WSAAI) 2025 Annual Meeting

Supporting Materials

Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Results of the CHAPTER-1 Open-Label Extension Study 748.6 KB

Dec 12 - Dec 15, 2024

APAAACI 2024 International Congress

Supporting Materials

RAPIDe-2 Study: Long-term Efficacy and Safety of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks 1.6 MB

Prophylaxis of Hereditary Angioedema Attacks With Oral Deucrictibant: Efficacy and Quality-of-Life Results from CHAPTER-1 1.4 MB

Long-Term Safety and Efficacy of Oral Deucrictibant for Hereditary Angioedema Prophylaxis: The CHAPTER-1 Open-Label Extension Study 1.4 MB

RAPIDe-3 Phase 3 Trial Design: Oral Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks 233 KB

Propensity Score-Matched Comparison of Outcomes for Deucrictibant vs Standard of Care in People Living with Hereditary Angioedema 646.2 KB

Dec 9 - Dec 10, 2024

BSI-CIPN Conference 2024

Supporting Materials

Characterizing the patient experience with current treatment of hereditary angioedema attacks in the United Kingdom 686.5 KB

Nov 17 - Nov 20, 2024

ISPOR Europe 2024

Supporting Materials

Challenges in Identifying Information to Build Economic Evaluations in Hereditary Angioedema 225.5 KB

Nov 6 - Nov 9, 2024

79th Annual CSACI Scientific Meeting

Supporting Materials

Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of HAE Attacks: Results of CHAPTER-1 Phase 2 238.1 KB

Long-term safety and efficacy of oral deucrictibant, a bradykinin B2 receptor antagonist, for prophylaxis in HAE: CHAPTER-1 extension study results 229.5 KB

Long-term efficacy and safety of oral bradykinin B2 receptor antagonist deucrictibant in treatment of HAE attacks: RAPIDe-2 extension study results 598.5 KB

Pagination

First page
Previous page
…
Page 3
Page 4
Current page 5
Page 6
Page 7
…
Next page
Last page

Presentations

Source:

EAACI Annual Congress 2026, Istanbul, Turkey

Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: End of Progression Results in the Phase 3 RAPIDe-3 Trial

Source:

EAACI Annual Congress 2026, Istanbul, Turkey

A Clinically Validated Kinin Biomarker Assay to Differentiate Bradykinin-Mediated from Mast Cell-Mediated Angioedema

Source:

EAACI Annual Congress 2026, Istanbul, Turkey

Clinical Cardiovascular Safety Assessment of Oral Deucrictibant

Latest Corporate Presentation

©2026 Pharvaris N.V. © All Rights Reserved

Menu

Privacy Policy
Clinical Trial Privacy Notice
Global Privacy Laws
Terms of Use

FOLLOW US